Prostate cancer pill from J&J could extend life by 4 months

Prostate cancer pill from J&J could extend life by 4 months

Prostate cancer pill from Johnson & Johnson could become the next big thing in the prostate cancer treatment market, as the clinical study has proved this pill has extended the life of prostate cancer patients by approx four months.

Johnson & Johnson’s ‘Abiraterone’ might hit the market in 2011. This new prostate cancer drug development by J&J could bring some big changes in the area of prostate cancer treatment.

There have been lots of researches and studies going on around the globe to treat aggressive prostate cancer better.

In 2010, there are two prostate cancer treatments that were approved. With the clinical success of J&J’s prostate cancer pill, the company hopes to clinch some quick share in the market.

Johnson & Johnson will soon apply for the marketing rights in United States and in Europe as well. According to reports, J&J will file marketing applications by the end of 2010.

Unfortunately there aren’t many treatment options available for the aggressive prostate cancer patients. There are about some four to five prostate cancer drugs available for the patients.

Considering the background of this disease and its treatment, the 3.9 month survival period can be considered as a good prostate cancer treatment option.